Liquid Formulation of Belumosudil - Kadmon Corporation

USPTO published patent application US20260097036A1 directed to liquid formulations of belumosudil, an immunosuppressive compound. The application discloses pharmaceutical compositions comprising belumosudil with various excipients and processes for preparing liquid formulations suitable for treating subjects.

For pharmaceutical companies and drug manufacturers, this published application signals Kadmon Corporation's patent protection strategy for belumosudil liquid dosage forms. While the application does not yet grant enforceable patent rights, it establishes a priority date of September 20, 2023. Competitors developing similar liquid formulations should review the claims upon issuance and consider freedom-to-operate analyses.